Overview

* Viatris Q3 2025 revenue beats analyst expectations, adjusted EPS also exceeds estimates

* Company acquires Aculys Pharma, gaining rights to pitolisant and Spydia in Japan

* Company returns over $920 mln to shareholders, including $500 mln in share repurchases

Outlook

* Viatris ( VTRS ) raises 2025 revenue guidance to $13.9 bln-$14.3 bln

* Company estimates 2025 adjusted EBITDA at $4.0 bln-$4.2 bln

* Viatris ( VTRS ) expects 2025 adjusted EPS of $2.25-$2.35

Result Drivers

* ACQUISITION IMPACT - Acquisition of Aculys Pharma expands product rights in Japan, contributing to growth

* CAPITAL RETURN - Over $920 mln returned to shareholders, including $500 mln in share repurchases

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $3.76 $3.61

Revenue bln bln (6

Analysts

)

Q3 Beat $0.67 $0.62 (6

Adjusted Analysts

EPS )

Q3 EPS -$0.11

Q3 NET -$128.20

INCOME mln

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 5 "hold" and 2 "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy."

* Wall Street's median 12-month price target for Viatris Inc ( VTRS ) is $12.00, about 10.4% above its November 5 closing price of $10.75

* The stock recently traded at 4 times the next 12-month earnings vs. a P/E of 4 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)